Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
MDAI · 10-Q filed August 11, 2026

MDAI earnings analysis

What we found in MDAI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results or detailed MD&A, so current-period financial metrics cannot be determined from the available text. The principal development is that disclosure controls remained ineffective as of June 30, 2026 because of a material weakness, although management has expanded finance staffing, upgraded ERP controls and initiated remediation testing. The filing states there were no material changes to the risk factors disclosed in the March 25, 2026 Form 10-K.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Expanded Finance Remediation Team
Management appointed a new Chief Financial Officer and supplemented accounting personnel as part of the remediation plan for the material weakness.
ERP and Control Enhancements
The company enhanced its enterprise resource planning system during 2025 to support key financial processes and enforce segregation of duties through automation and approval workflows.
Remediation Testing Underway
Management expects testing from the first and second quarters of 2026, plus testing in the second half of 2026, to support a conclusion that controls are appropriately designed and operating effectively.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Material Weakness Persists
As of June 30, 2026, disclosure controls and procedures were not effective because of a material weakness in internal control over financial reporting, including inconsistent financial-statement close, account-reconciliation, transaction-processing and reporting-review controls.
Uncertain Remediation Outcome
The company stated that the material weaknesses will continue to exist until remediation steps have been completed, operated for a sufficient period, and evaluated for effectiveness; it also cautioned that remediation may not be successful or prevent future weaknesses.
Control Remediation Timing Risk
Management's expected remediation conclusion depends on testing in the first and second quarters of 2026 and the second half of 2026, leaving execution and timing risk before effectiveness can be demonstrated.
Guidance

What they said about what is next.

The provided 10-Q text contains no quantitative revenue or EPS guidance. Management expects testing conducted during the first and second quarters of 2026, together with testing in the second half of 2026, to support a conclusion that controls are effective and the material weakness has been remediated.

How we read the filing overall

The filing reads about the same as the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-Q · May 12, 2026
MDAI reported Q1 2026 results reflecting a significant drop in research and development revenue and net income compared to the prior year. While revenue saw a notable beat against consensus estimates, the overall…
10-K · March 25, 2026
Spectral AI (MDAI) is positioning DeepView as a Day‑One AI diagnostic for burn wound healing with a large government‑funded development runway. The company reports completed enrollment for its De Novo validation (164…
10-Q · November 13, 2025
Spectral AI reported Q3 research & development revenue of $3,792,000 (Q3 2025), down from $8,173,000 in Q3 2024, with a net loss of $3,552,000 (loss per share $0.13). Cash improved to $10,495,000 as of September 30,…
10-Q · May 15, 2025
Spectral AI reported research and development revenue of $6.707M for the quarter ended March 31, 2025 and achieved net income of $2.897M (basic EPS $0.13, diluted $0.11), driven largely by a $4.253M non-cash gain from a…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing MDAI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever